In vivo pharmacological actions of F 11356, a novel high efficacy anti-migraine 5-HT1B/D receptor agonist.

被引：0
|
作者：
John, GW [1 ]
Verscheure, Y [1 ]
Infanti, F [1 ]
Bel, L [1 ]
Perez, M [1 ]
Halazy, S [1 ]
Chopin, P [1 ]
Marien, M [1 ]
Colpaert, FC [1 ]
机构：
[1] Ctr Rech Pierre Fabre, F-81106 Castres, France
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1998年 / 358卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P5261
引用
收藏
页码：R523 / R523
页数：1
相关论文
共 50 条
  • [31] Donitriptan mesilate -: F-12640 -: Antimigraine -: 5-HT1B/1D agonist
    不详
    DRUGS OF THE FUTURE, 2001, 26 (06) : 588 - 588
  • [32] Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
    Martin, GR
    Robertson, AD
    MacLennan, SJ
    Prentice, DJ
    Barrett, VJ
    Buckingham, J
    Honey, AC
    Giles, H
    Moncada, S
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (02) : 157 - 164
  • [33] Cortical spreading depression is modulated by 5-ht1B/1D receptor agonist naratriptan
    Supronsinchai, W.
    Hoffmann, J.
    Goadsby, P. J.
    CEPHALALGIA, 2011, 31 (01) : 107 - 107
  • [34] Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat
    Pagniez, F
    Valentin, JP
    Vieu, S
    Colpaert, FC
    John, GW
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (02) : 205 - 214
  • [35] Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine
    MacLennan, SJ
    Cambridge, D
    Whiting, MV
    Marston, C
    Martin, GR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 361 (2-3) : 191 - 197
  • [36] PHARMACOLOGICAL PROFILE OF (-)HT-90B, A NOVEL 5-HT1A RECEPTOR AGONIST 5-HT2 RECEPTOR ANTAGONIST
    UCHIDA, H
    INAGAWA, K
    TAMEDA, C
    MIYAUCHI, T
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1995, 19 (07) : 1201 - 1216
  • [37] The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine
    Raffaelli, Bianca
    Israel, Heike
    Neeb, Lars
    Reuter, Uwe
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1409 - 1415
  • [38] Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine:: a multicentre, dose-range finding study
    Dahlof, C
    Diener, HC
    Goadsby, PJ
    Massiou, H
    Olesen, J
    Schoenen, J
    Wilkinson, M
    Sweet, RM
    Klein, KB
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (06) : 535 - 543
  • [39] Donitriptan, a unique high-efficacy 5-HT1B/1D agonist:: Key features and acute antimigraine potential
    John, GW
    Perez, M
    Pauwels, PJ
    Le Grand, B
    Verscheure, Y
    Colpaert, FC
    CNS DRUG REVIEWS, 2000, 6 (04): : 278 - 289
  • [40] Rizatriptan, a novel 5-HT1B/1D agonist for migraine:: Single- and multiple-dose tolerability and pharmacokinetics in healthy subjects
    Goldberg, MR
    Lee, Y
    Vyas, KP
    Slaughter, DE
    Panebianco, D
    Ermlich, SJ
    Shadle, CR
    Brucker, MJ
    McLoughlin, DA
    Olah, TV
    JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) : 74 - 83
12345